Form 4: PTC Therapeutics Director Gains Equity Incentives

PTC Therapeutics Director Mary L. Smith acquired 4,000 restricted stock units and 3,475 stock options on January 2, 2026.

Summary

• Mary L. Smith, a Director of PTC Therapeutics, Inc. (PTCT), reported transactions on January 2, 2026.
• Acquired 4,000 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a transaction price of $0.
• These RSUs will vest over one year, with 5/12 of the shares vesting on June 2, 2026, and the remaining 7/12 vesting on January 2, 2027.
• Acquired 3,475 Stock Options (Right to Buy) with an exercise price of $76.74, also at a transaction price of $0.
• These options were granted on January 2, 2026, and will vest over one year in twelve equal monthly installments, commencing on February 2, 2026.
• Following these transactions, Mary L. Smith beneficially owns 21,813 shares of Common Stock and 3,475 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The filing reports a routine equity grant to a director, which is generally seen as a positive for aligning management incentives with shareholder interests, though it's not an open market purchase.

Positives

• Director Mary L. Smith received equity grants (RSUs and stock options), which aligns her interests with those of shareholders.
• The grants represent a commitment to the company's long-term performance through structured vesting schedules.

Future Outlook

The grants indicate future vesting events for both RSUs and stock options, aligning director incentives with future company performance over the next year and beyond.

Industry Context

Granting restricted stock units and stock options to directors is a common practice in the biotechnology and pharmaceutical industry, as well as across publicly traded companies, to incentivize long-term performance and align leadership interests with shareholder value.

Stakeholder Impact

• Shareholders: The director's interests are further aligned with shareholder value creation through these equity incentives.

Next Steps

• Vesting of 5/12 of the Restricted Stock Units on June 2, 2026.
• Vesting of the remaining 7/12 of the Restricted Stock Units on January 2, 2027.
• Monthly vesting of stock options commencing February 2, 2026, over one year.

Key Dates

Keywords

PTC Therapeutics, PTCT, Form 4, insider transaction, director compensation, restricted stock units, stock options, equity grant, beneficial ownership